ClinicalTrials.gg
RecruitingNCT07946523PSICOGAMEUpdated Nov 18, 2026

Andy's Mind: A Co-created Serious Game for People With Psychosis (PSICOGAME)

An interventional study of Andy's Mind and Conventional group psychoeducation in Schizophrenia Spectrum and Other Psychotic Disorders, SCHIZOPHRENIA 1 (Disorder) and Schizoaffective Disorder, sponsored by Fundació Sant Joan de Déu. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionPsychotic DisordersRegistry: Schizophrenia Spectrum and Other Psychotic DisordersReclassifiedWhy we changed it
Registry
Schizophrenia Spectrum and Other Psychotic Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Psychotic Disorders
Why
  1. The study's listed conditions name Psychotic Disorders, a narrower term within Schizophrenia Spectrum and Other Psychotic Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundació Sant Joan de Déu · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2026, registered Nov 2026).
  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 65 studies in Psychotic Disorders with a site in Spain — 15 open to participants now, 19 under way, 4 of them phase 3. Psychotic Disorders · Spain.

Planned enrollment
34th of 49
80 · median 160
Started
2026
with 2 others
No phase
23 of 65
8 open now
Primary completion
2027-09
later than 13 of 18 live
Registered
65th of 65
by date
Lead sponsor
6 of 65
Fundació Sant Joan de Déu

Among the 65 studies in Psychotic Disorders with a site in Spain, this one is the 34th largest by planned enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2026, is one of 23 with no phase, reaches primary completion later than 13 of the 18 other live ones, and was the 65th registered.

Psychotic Disorders

1,591 studies on the registry are indexed under Psychotic Disorders; 282 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

15 of the 65 studies in Psychotic Disorders with a site in Spain are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 205 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 143 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Psychotic Disorders with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether Andy's Mind, a psychoeducational card game co-created with a person with lived experience of psychosis, improves illness awareness (insight) and attitudes toward treatment in adults with schizophrenia spectrum and other psychotic disorders, compared with conventional group psychoeducation.

The main questions it aims to answer are:

  • Does Andy's Mind improve insight into mental disorder more than conventional psychoeducation?
  • Does Andy's Mind improve attitudes toward medication, as an indicator of treatment adherence, more than conventional psychoeducation?

Researchers will also look at psychotic symptoms, attitudes toward alcohol and other drugs, and participant satisfaction.

Participants will:

  • Be randomly assigned to one of two groups: the Andy's Mind game group or a conventional psychoeducation group.
  • Attend 8 weekly group sessions of 45 minutes. Both groups cover the same topics: what psychosis is, symptoms, treatment, side effects, substance use and relapse prevention.
  • Complete interviews and questionnaires before the sessions, right after the last session, and two months later.

The study takes place in mental health services in Catalonia, Spain, including prison mental health units, psychosocial rehabilitation services and community mental health centers.

Read the detailed description

Background Poor insight and low adherence to antipsychotic treatment are common in people with psychotic disorders and are associated with relapse and rehospitalization. Group psychoeducation is an evidence-based intervention that improves illness awareness and adherence, but many patients have difficulty understanding and integrating the information delivered in conventional formats, particularly in settings with cognitive, language and cultural barriers such as prison mental health units. Serious games may increase intrinsic motivation, participation and peer interaction, and reduce the hierarchical structure of conventional psychoeducation. To date, no analog serious game for psychoeducation in psychosis has been evaluated in a randomized controlled trial.

Intervention development The study has two phases. In Phase 1, Andy's Mind was developed through participatory co-design with mental health professionals and a person with lived experience of psychosis, who also illustrated the cards, and was tested in a usability pilot in two prison mental health units (n=10). Phase 1 participants are not eligible for Phase 2. This registration corresponds to Phase 2, the randomized controlled trial.

Experimental intervention Andy's Mind is an analog card game for 2 to 6 players. It uses a science-fiction narrative in which psychotic symptoms are represented as creatures that players learn to stabilize using treatment and protective factors while facing relapse risks such as substance use or sleep deprivation. The final version includes 104 cards in seven categories (symptom, treatment, side effect, protection, attack/relapse, boom and wild cards), with images and text in Spanish, English and Arabic and high-contrast color coding. The intervention consists of 8 weekly group sessions of 45 minutes with 4 to 6 participants: sessions 1 and 2 introduce the rules and the meaning of each card, and sessions 3 to 8 consist of gameplay followed by 5 to 10 minutes of questions to check understanding. Sessions are led by mental health professionals trained by the research team using a facilitator manual.

Active comparator Conventional group psychoeducation based on the PIENSA program, with the same dose (8 weekly sessions of 45 minutes, groups of 4 to 8 participants) and the same content: what psychosis is (session 1), symptoms (sessions 2 and 3), treatments (session 4), side effects (session 5), drugs and psychosis (session 6), relapse prevention, protective and precipitating factors (session 7), and review (session 8).

Design and randomization Multicenter, two-arm, parallel-group, open-label randomized controlled trial. Eighty participants (40 per arm) are recruited by consecutive sampling. Allocation follows a randomization sequence generated by a person external to the research team and linked to the consecutive participant code. Assessments are carried out by members of the research team who do not deliver the interventions; assessors are not blinded to group allocation.

Assessments Participants are assessed at baseline (T0), immediately after the 8-session intervention (T1) and at a 2-month follow-up (T2). Cognitive screening with the SCIP-S is performed at baseline only, as an exclusion criterion. Sociodemographic and clinical data, including a descriptive substance use questionnaire, are collected at baseline. Questionnaires are completed on paper or directly in REDCap depending on device availability and unit regulations; paper data are transcribed into REDCap by the principal investigator.

Sample size and analysis With alpha 0.05 (one-sided) and 80% power, 80 participants allow detection of an effect size of Cohen's d = 0.63 in the between-group comparison at T1 using ANCOVA adjusted for baseline scores, assuming a pre-post correlation of 0.2. The main analysis follows the intention-to-treat principle and compares groups at T1 and T2 with ANCOVA adjusted for baseline values. Care setting (prison, community, rehabilitation) will be considered as a covariate. Change over time will also be explored with repeated-measures or linear mixed models including group, time and group-by-time interaction. A per-protocol analysis will be performed as a complementary analysis.

03

Conditions studied

  • Schizophrenia Spectrum and Other Psychotic Disorders
  • SCHIZOPHRENIA 1 (Disorder)
  • Schizoaffective Disorder
  • Psychotic Disorders

Keywords

  • Serious game
  • Card game
  • Game-based intervention
  • Psychoeducation
  • Insight
  • Illness awareness
  • Medication adherence
  • Co-design
  • Lived experience
  • Forensic psychiatry
  • Prison mental health
  • Psychosocial rehabilitation
04

In context

Psychotic Disorders Reclassified

1,591 studies on the registry are indexed under Psychotic Disorders; 282 are open to participants now.

This study's planned enrollment of 80 is above the median of 65 across 1,324 interventional studies indexed under Psychotic Disorders.

Browse Psychotic Disorders studies →

Lead sponsor

Fundació Sant Joan de Déu is the lead sponsor of 72 studies on the registry; 21 are open to participants now.

Compared within Psychotic Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Schizophrenia Spectrum and Other Psychotic Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years, inclusive.
  • Diagnosis within the schizophrenia spectrum and other psychotic disorders according to : schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder, substance/medication-induced psychotic disorder, psychotic disorder due to another medical condition, or unspecified psychotic disorder.
  • Receiving care in a prison, community or rehabilitation mental health service.
  • Signed from the participant and, when applicable, from the legal guardian.

Exclusion criteria

Exclusion Criteria:

  • Moderate or severe intellectual disability.
  • Cognitive impairment on the Screen for Cognitive Impairment in Psychiatry, Spanish version (SCIP-S), defined as a total score below the 5th percentile or any subscale score below the 3rd percentile according to clinical-sample norms adjusted for age and educational level.
  • Active psychotic episode.
  • Language barrier preventing completion of the assessments or participation in the group sessions.
  • Previous participation in the Phase 1 usability pilot of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Andy's Mind serious game

    Participants attend 8 weekly group sessions of 45 minutes (4 to 6 participants per group) using the Andy's Mind psychoeducational card game, led by trained mental health professionals.

    Behavioral: Andy's Mind

  • Active comparator
    Conventional psychoeducation

    Participants attend 8 weekly group sessions of 45 minutes (4 to 8 participants per group) of conventional psychoeducation based on the PIENSA program, covering the same topics as the experimental arm.

    Behavioral: Conventional group psychoeducation

Interventions

  • BehavioralAndy's Mind

    Analog psychoeducational card game for 2 to 6 players, co-designed with mental health professionals and a person with lived experience of psychosis. Psychotic symptoms are represented as creatures that players stabilize using treatment and protective factors while facing relapse risks. 104 cards in seven categories (symptom, treatment, side effect, protection, attack/relapse, boom and wild cards), with text in Spanish, English and Arabic. Sessions 1-2: introduction to rules and cards. Sessions 3-8: gameplay followed by 5-10 minutes of questions to check understanding.

  • BehavioralConventional group psychoeducation

    Structured group psychoeducation based on the PIENSA program. Session 1: what is psychosis. Sessions 2-3: symptoms. Session 4: treatments. Session 5: side effects. Session 6: drugs and psychosis. Session 7: relapse prevention, protective and precipitating factors. Session 8: review and questions.

07

What researchers measure

Primary outcomes

  1. Insight into mental disorder (Scale to Assess Unawareness of Mental Disorder, SUMD)

    Insight assessed with the Spanish version of the SUMD, a clinician-rated semi-structured interview that evaluates awareness of having a mental disorder, awareness of the effects of medication and awareness of the social consequences of the disorder, plus awareness and attribution of 17 specific symptoms. Items are scored from 1 (aware) to 5 (unaware); higher scores indicate lower insight. Between-group comparison of post-intervention scores adjusted for baseline.

    Time frame: Baseline and immediately after the 8-week intervention

  2. Attitudes toward antipsychotic medication as an indicator of treatment adherence (Drug Attitude Inventory, DAI-10)

    Self-reported attitudes and beliefs about psychiatric medication assessed with the Spanish version of the 10-item Drug Attitude Inventory (DAI-10). Each item is scored +1 or -1; total score ranges from -10 to +10, with higher scores indicating more positive attitudes toward medication. Between-group comparison of post-intervention scores adjusted for baseline.

    Time frame: Baseline and immediately after the 8-week intervention

Secondary outcomes

  1. Maintenance of insight (SUMD) at follow-up

    SUMD scores as described for the primary outcome, compared between groups at 2-month follow-up adjusted for baseline. Higher scores indicate lower insight.

    Time frame: Baseline and 2 months after the end of the intervention

  2. Maintenance of attitudes toward medication (DAI-10) at follow-up

    DAI-10 total score (range -10 to +10; higher scores indicate more positive attitudes toward medication), compared between groups at 2-month follow-up adjusted for baseline.

    Time frame: Baseline and 2 months after the end of the intervention

  3. Psychotic symptom severity (Positive and Negative Syndrome Scale, PANSS)

    Clinician-rated severity of positive, negative and general psychopathology symptoms assessed with the 30-item PANSS. Each item is scored from 1 (absent) to 7 (extreme); total score ranges from 30 to 210, with higher scores indicating greater symptom severity. Total and subscale scores will be analyzed.

    Time frame: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

  4. Attitudes toward alcohol (Escala de Actitudes hacia el Alcohol, ESACAL)

    Self-reported attitudes toward alcohol assessed with the 13-item ESACAL, rated on a 5-point Likert scale (total score range 13 to 65). Items unfavorable to health are reverse-scored, so higher scores indicate attitudes more favorable to health.

    Time frame: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

  5. Attitudes toward other drugs (Escala de Actitudes hacia otras Drogas, ESACDRO)

    Self-reported attitudes toward drugs other than alcohol assessed with the 13-item ESACDRO, rated on a 5-point Likert scale (total score range 13 to 65). Items unfavorable to health are reverse-scored, so higher scores indicate attitudes more favorable to health.

    Time frame: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

  6. Satisfaction and engagement with the intervention

    Self-reported satisfaction and engagement with the intervention assessed with an ad hoc questionnaire rated on a 5-point Likert scale (1 to 5), with higher scores indicating greater satisfaction. Compared between groups.

    Time frame: Immediately after the 8-week intervention

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in publications (sociodemographic variables and SUMD, DAI-10, PANSS, ESACAL, ESACDRO and satisfaction scores) will be available upon reasonable request. Because the sample includes people in prison mental health settings, a vulnerable population, data will not be deposited in an open repository and will only be shared under a data sharing agreement, for purposes consistent with the informed consent.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 6 months after publication of the main results and for 5 years thereafter.

Access criteria: Researchers who provide a methodologically sound proposal approved by an ethics committee may request access by contacting the principal investigator. Access requires approval by the sponsor (Fundació per a la Recerca i la Docència Sant Joan de Déu) and the signing of a data sharing agreement in compliance with the EU General Data Protection Regulation.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.

Of 459 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 19 months is below that.

Counting every sponsor, half of 461 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07946523
Lead sponsor
Fundació Sant Joan de Déu
Collaborators
Parc Sanitari Sant Joan de Déu, Althaia Xarxa Assistencial Universitària de Manresa, Col·legi Oficial Infermeres de Barcelona
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Feb 16, 2026
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Andrea Fontán Abeijón, RN, BSc
Contact
andrea.fontan@sjd.es
+34687343637
Gemma Escuder Romeva, PhD
Contact
gemma.escuder@sjd.es
Andrea Fontán Abeijón, RN, BSc
principal investigator · Parc Sanitari Sant Joan de Déu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion